Cohen's SAC Capital Discloses 8.6% Stake In Rocket-Stock Vanda (VNDA)
More News related to VNDA
- Vanda Pharma (VNDA) Tops by 3c, Posts Q3 Loss of $0.28
- Vanda Pharmaceuticals Reports Third Quarter 2009 Results
- Vanda Pharmaceuticals to Announce Third Quarter 2009 Financial Results on November 2, 2009
- Vanda (VNDA) and Novartis (NVS) to Develop Fanapt in US and Canada
- Novartis Pharma Acquires Exclusive Rights From Vanda Pharmaceuticals for Commercialization of Fanapt(TM) in the United States and Canada
In a 13G filing on Vanda Pharmaceuticals, Inc. (Nasdaq: VNDA), Steven Cohen's SAC Capital hedge fund disclosed an 8.6% stake, or 2,279,423 shares, in the company. A 13G indiates a 'passive investment' over 5%.
Shares of have surged over 10x since announcing FDA approval for its schizophrenia drug in early-May.
Related Categories
13GsMomentum Movers
Stocks Mentioned
+0.17Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
